View source for HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements

{{DISPLAYTITLE:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements}}
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]

{{Under Construction}}

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements]].
}}</blockquote>

<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>

==Primary Author(s)*==

Kate Berry, MBBS, BBus (Hons), Pathology Queensland

__TOC__

==Cancer Category / Type==

High-grade B-cell lymphoma

==Cancer Sub-Classification / Subtype==

Put your text here 

==Definition / Description of Disease==

Put your text here <span style="color:#0070C0">(''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories referring to the specific WHO book pages, diagnostic criteria if applicable, and differential diagnosis if applicable'') </span>

==Synonyms / Terminology==

Put your text here <span style="color:#0070C0">(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'') </span>

==Epidemiology / Prevalence==

Put your text here

==Clinical Features==

Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>
{| class="wikitable"
|'''Signs and Symptoms'''
|EXAMPLE Asymptomatic (incidental finding on complete blood counts)

EXAMPLE B-symptoms (weight loss, fever, night sweats)

EXAMPLE Fatigue

EXAMPLE Lymphadenopathy (uncommon)
|-
|'''Laboratory Findings'''
|EXAMPLE Cytopenias

EXAMPLE Lymphocytosis (low level)
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}

Patients typically show Ann Arbor stage IV disease at diagnosis<ref name=":20" /> with involvement of more than one extra-nodal site and a high International Prognostic Index (IPI) score<ref name=":0" /><ref name=":1" /><ref name=":5">{{Cite journal|last=Xia|first=Yang|last2=Zhang|first2=Xinlian|date=2020|title=The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma|url=https://www.karger.com/Article/FullText/505892|journal=Acta Haematologica|language=en|volume=143|issue=6|pages=520–528|doi=10.1159/000505892|issn=0001-5792}}</ref>. B symptoms (fever, night sweats and weight loss) are common at diagnosis, as is poor performance status<ref name=":1" /><ref name=":3" /><ref name=":5" />. Patients almost invariably show elevated serum lactate dehydrogenase and, less frequently, leucocytosis<ref name=":1" /><ref name=":2" /><ref name=":3" /><ref name=":4" /><ref name=":5" />.

</blockquote>
==Sites of Involvement==

·        Lymph nodes

·        Extra-nodal sites

·        Bone marrow

·        Central nervous system

==Morphologic Features==

The morphological appearances of HGBL-DH/TH are variable, and histology alone is an unreliable predictor of double- or triple-hit status<ref name=":10">{{Cite journal|last=Nguyen|first=Lynh|last2=Papenhausen|first2=Peter|last3=Shao|first3=Haipeng|date=2017-04-05|title=The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects|url=http://www.mdpi.com/2073-4425/8/4/116|journal=Genes|language=en|volume=8|issue=4|pages=116|doi=10.3390/genes8040116|issn=2073-4425|pmc=PMC5406863|pmid=28379189}}</ref>. Recognised morphologies include features of diffuse large B cell lymphoma (DLBCL), NOS, with a diffuse growth pattern, variably sized nuclei with irregular nuclear contours, often with plentiful basophilic cytoplasm and variable numbers of mitotic figures and tingible-body macrophages;  Burkitt-like cytomorphology, with a diffuse proliferation of medium-sized to large, often very monomorphic, lymphoid cells with intermixed tingible-body macrophages and plentiful mitotic and apoptotic figures, imparting a “starry-sky” appearance; or an intermediate appearance with sheets of medium-sized cells with finely granular blastoid-like nuclear chromatin, inconspicuous nucleoli and scant cytoplasm.<ref name=":0" /><ref name=":3" /><ref name=":4" />.

==Immunophenotype==

When classified by cell of origin based on immunohistochemistry according to the Hans algorithm<ref>{{Cite journal|last=Hans|first=C. P.|date=2004-01-01|title=Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray|url=http://www.bloodjournal.org/cgi/doi/10.1182/blood-2003-05-1545|journal=Blood|language=en|volume=103|issue=1|pages=275–282|doi=10.1182/blood-2003-05-1545|issn=0006-4971}}</ref>, the vast majority (70-90%) of HGBL-DH/TH are of germinal-centre B-type<ref name=":1" /><ref name=":7" /><ref name=":2" /><ref name=":8" /><ref name=":9" /><ref name=":4" /><ref name=":13">{{Cite journal|last=Visco|first=C.|last2=Tzankov|first2=A.|last3=Xu-Monette|first3=Z. Y.|last4=Miranda|first4=R. N.|last5=Tai|first5=Y. C.|last6=Li|first6=Y.|last7=Liu|first7=W.-m.|last8=d'Amore|first8=E. S. G.|last9=Li|first9=Y.|date=2013-02-01|title=Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study|url=http://www.haematologica.org/cgi/doi/10.3324/haematol.2012.066209|journal=Haematologica|language=en|volume=98|issue=2|pages=255–263|doi=10.3324/haematol.2012.066209|issn=0390-6078|pmc=PMC3561433|pmid=22929980}}</ref><ref name=":11">{{Cite journal|last=Rosenwald|first=Andreas|last2=Bens|first2=Susanne|last3=Advani|first3=Ranjana|last4=Barrans|first4=Sharon|last5=Copie-Bergman|first5=Christiane|last6=Elsensohn|first6=Mad-Helenie|last7=Natkunam|first7=Yaso|last8=Calaminici|first8=Maria|last9=Sander|first9=Birgitta|date=2019-12-10|title=Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium|url=https://ascopubs.org/doi/10.1200/JCO.19.00743|journal=Journal of Clinical Oncology|language=en|volume=37|issue=35|pages=3359–3368|doi=10.1200/JCO.19.00743|issn=0732-183X}}</ref>. This is especially true of HGBL with MYC and BCL2 translocation which is overwhelmingly shown to be of germinal centre origin, as per the Hans algorithm or by cell of origin gene expression profiling<ref name=":6" /><ref name=":8" />. Some authors regard this entity, along with triple hit cases, to be exclusively germinal centre B-cell derived and believe the small numbers of ABC cases identified by some studies to have been misclassified as a result of cell of inaccurate cell of origin testing<ref name=":6" />. 

HGBL with MYC and BCL6 translocation is a more heterogenous entity with both germinal centre b-cell-like and activated b-cell-like cases occurring<ref name=":7" /><ref name=":8" /><ref name=":11" />.

Although HGBL-DH/TH includes a significantly higher proportion of tumours with immunohistochemically detectable overexpression of MYC and BCL2 and/or BCL6 than DLBCL as a whole<ref name=":6" />, in the absence of confirmed gene rearrangements this is insufficient for diagnosis<ref name=":0" />. The high prevalence of C-MYC protein expression in DLBCL in the absence of chromosomal translocation suggests alternative mechanisms may lead to similar overexpression, such as MYC gene mutations or amplifications<ref name=":10" /><ref name=":14">{{Cite journal|last=Riedell|first=Peter A.|last2=Smith|first2=Sonali M.|date=2018-12-15|title=Double hit and double expressors in lymphoma: Definition and treatment|url=https://onlinelibrary.wiley.com/doi/10.1002/cncr.31646|journal=Cancer|language=en|volume=124|issue=24|pages=4622–4632|doi=10.1002/cncr.31646|issn=0008-543X}}</ref>.

Although the proliferative index of these tumours is variable, in contrast to Burkitt lymphoma the Ki67 staining rate is is predominantly lower than 90% when measured by immunohistochemistry<ref name=":8" />.
{| class="wikitable sortable"
|-
!Finding!!Marker
|-
|Positive (almost universal)||CD20
|-
|Positive (typically)||CD10, BCL2, BCL6, MYC, MIB-1
|-
|Negative (almost universal)||CD3, cyclin D1, TdT
|-
|Negative (typically)||CD5, MUM1, EBER
|}

==Chromosomal Rearrangements (Gene Fusions)==

Put your text here and fill in the table

{| class="wikitable sortable"
|-
!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence
!Diagnostic Significance (Yes, No or Unknown)
!Prognostic Significance (Yes, No or Unknown)
!Therapeutic Significance (Yes, No or Unknown)
!Notes
|-
|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC)
EXAMPLE 30% (add reference)
|Yes
|No
|Yes
|EXAMPLE

The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).
|}		
			

<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}

This subtype of B-cell lymphoma is defined by a rearrangement of the MYC proto-oncogene, located on chromosome 8q24.  In 39-65% of cases the translocation partner is an immunoglobulin gene, most commonly the IGH region on chromosome 14q32 with the IGK (2p12) and IGL (22q11.2) gene loci less frequently involved<ref name=":0" /><ref name=":7" /><ref name=":2" /><ref name=":8" /><ref name=":4" /><ref>{{Cite journal|last=Pedersen|first=Mette Ø.|last2=Gang|first2=Anne O.|last3=Poulsen|first3=Tim S.|last4=Knudsen|first4=Helle|last5=Lauritzen|first5=Anne F.|last6=Nielsen|first6=Signe L.|last7=Klausen|first7=Tobias W.|last8=Nørgaard|first8=Peter|date=2014-01|title=MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations|url=https://onlinelibrary.wiley.com/doi/10.1111/ejh.12212|journal=European Journal of Haematology|language=en|volume=92|issue=1|pages=42–48|doi=10.1111/ejh.12212}}</ref>. Non-IG gene partners include 9p13 and 3q27.3 (BCL6)<ref name=":8" />. Additionally, all cases must harbour a BCL2 (18q21.3) and/or BCL6 (3q27.3) rearrangement. 

{| class="wikitable sortable"
|-
!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence
|-
|t(8;14)(q24;q32)||IGH-MYC||der(14)||28%<ref name=":22">{{Cite journal|last=Chong|first=Lauren C.|last2=Ben-Neriah|first2=Susana|last3=Slack|first3=Graham W.|last4=Freeman|first4=Ciara|last5=Ennishi|first5=Daisuke|last6=Mottok|first6=Anja|last7=Collinge|first7=Brett|last8=Abrisqueta|first8=Pau|last9=Farinha|first9=Pedro|date=2018-10-23|title=High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology|url=https://ashpublications.org/bloodadvances/article/2/20/2755/16113/Highresolution-architecture-and-partner-genes-of|journal=Blood Advances|language=en|volume=2|issue=20|pages=2755–2765|doi=10.1182/bloodadvances.2018023572|issn=2473-9529|pmc=PMC6199666|pmid=30348671}}</ref>
|-
|t(8;22)(q24;q11)||MYC-IGL||der(8)|| rowspan="2" |7%<ref name=":22" />
|-
|t(2;8)(p12;q24)
|MYC-IGK
|der(8)
|-
|t(14;18)(q32;q21.3)
|IGH-BCL2
|der(14)
|
|-
|t(2;18)(p11;q21.3)
|BCL2-IGK
|
|
|-
|t(18;22)(q21.3;q11)
|BCL2-IGL
|
|
|-
|t(3;14)(q27;q32)
|IGH-BCL6
|
|
|}
</blockquote>


<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in:
* Chromosomal Rearrangements (Gene Fusions)
* Individual Region Genomic Gain/Loss/LOH
* Characteristic Chromosomal Patterns
* Gene Mutations (SNV/INDEL)}}

In general, patients with germinal centre B type DLBCL have been shown to have a better prognosis than those with ABC-type tumours<ref name=":13" />. However, despite the fact that the majority of HGBL DH/TH tumours are of GCB subtype, concurrent MYC and BCL2 and/or BCL6 rearrangement confers significantly worse outcomes than tumours without concurrent translocations<ref name=":1" /><ref name=":2" /><ref name=":5" /><ref name=":13" /><ref name=":11" />, with median progression free and overall survival of approximately 10 and 22 months, respectively, despite treatment<ref name=":1" /><ref name=":3" />. The extremely poor outcomes in these patients are postulated to result from the synergistic dysregulation of both genes, leading to MYC-induced growth promotion and inhibition of apoptosis resulting from BCL2 rearrangement<ref name=":1" />. Amongst HGBL DH/TH patients, advanced stage, central nervous system involvement, leucocytosis and LDH>3 times the upper limit of normal are all associated with poorer outcomes<ref name=":3" /> <sup> </sup>There appears to be no significant survival difference between patients with double hit (either BCL2 or BCL6) tumours and those with a triple hit<ref name=":7" /><ref name=":8" /><ref name=":11" />.

The partner gene involved in MYC translocation also affects prognosis, with an IG partner gene conferring a significantly shorter progression free and overall survival<ref name=":7" /><ref name=":22" />. Patients with double hit lymphoma with an IG-MYC translocation have significantly worse survival than patients with a non-IG partner gene and patients without a double hit, even in studies in which double hit has not shown to be independently associated with poorer outcomes overall. Several studies <ref name=":7" /><ref name=":11" /> have shown that, regardless of double or triple hit status, DLBCL patients with MYC rearrangement to an IG partner have a shorter overall survival than patients without MYC rearrangement and in one large study patients with double or triple hit lymphoma with MYC translocation to a non-IG partner did not show any significant difference in outcomes to patients with DLBCL without MYC rearrangement<ref name=":11" />. This reinforces the need for identification of the MYC translocation partner via appropriate FISH probe selection. 

Further investigation of HGBL DH/TH via gene expression profiling in newer studies has reinforced that heterogeneity in outcomes exists amongst these patients, and that further sub classification via gene expression profiling and/or mutation analysis may be necessary to provide accurate prognostication. 

Song et al<ref name=":18" /> in a study of 87 cases of de novo DLBCL of germinal centre type treated with R-CHOP defined a subset of cases as “double-hit” on the basis of gene expression profiling (DHsig+), with most but not all cases showing double- or triple-hits on FISH. In this cohort, patients with DHsig+ and TP53 mutation had the worst overall and progression free survival, with good overall survival in DHsig+ patients without TP53 abnormalities. These mutations have been postulated to lead to a highly aggressive phenotype through evasion of apoptosis driven by BCL2 in the absence of TP53 mediation<ref name=":15" />.

First-line treatment for HGBL is rituximab in combination with intensive chemotherapy, most commonly CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) with or without CNS prophylaxis<ref name=":16" />. Some studies have shown intensive induction regimens such as R-EPOCH to be associated with an improved response rate and progression free survival<ref name=":3" /><ref name=":20">{{Cite journal|last=Oki|first=Yasuhiro|last2=Noorani|first2=Mansoor|last3=Lin|first3=Pei|last4=Davis|first4=Richard E.|last5=Neelapu|first5=Sattva S.|last6=Ma|first6=Long|last7=Ahmed|first7=Mohamed|last8=Rodriguez|first8=Maria Alma|last9=Hagemeister|first9=Fredrick B.|date=2014-09|title=Double hit lymphoma: the MD Anderson Cancer Center clinical experience|url=https://onlinelibrary.wiley.com/doi/10.1111/bjh.12982|journal=British Journal of Haematology|language=en|volume=166|issue=6|pages=891–901|doi=10.1111/bjh.12982}}</ref>. In vitro studies of novel targeted agents such as BET inhibitors both alone and in combination with BCL-2 and MDM2-p53 inhibitors have shown promising results<ref>{{Cite journal|last=Deng|first=Manman|last2=Xu-Monette|first2=Zijun Y.|last3=Pham|first3=Lan V.|last4=Wang|first4=Xudong|last5=Tzankov|first5=Alexandar|last6=Fang|first6=Xiaosheng|last7=Zhu|first7=Feng|last8=Visco|first8=Carlo|last9=Bhagat|first9=Govind|date=2021-02|title=Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents|url=https://pubmed.ncbi.nlm.nih.gov/33154093|journal=Molecular cancer research: MCR|volume=19|issue=2|pages=249–260|doi=10.1158/1541-7786.MCR-20-0466|issn=1557-3125|pmc=8092941|pmid=33154093}}</ref> and further investigation of targeted therapies are needed to improve the otherwise dismal overall prognosis of these tumours.

</blockquote>
==Individual Region Genomic Gain / Loss / LOH==

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>

{| class="wikitable sortable"
|-
!Chr #!!Gain / Loss / Amp / LOH!!Minimal Region Genomic Coordinates [Genome Build]!!Minimal Region Cytoband
!Diagnostic Significance (Yes, No or Unknown)
!Prognostic Significance (Yes, No or Unknown)
!Therapeutic Significance (Yes, No or Unknown)
!Notes
|-
|EXAMPLE

7
|EXAMPLE Loss
|EXAMPLE

chr7:1- 159,335,973 [hg38]
|EXAMPLE

chr7
|Yes
|Yes
|No
|EXAMPLE

Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).
|-
|EXAMPLE

8
|EXAMPLE Gain
|EXAMPLE

chr8:1-145,138,636 [hg38]
|EXAMPLE

chr8
|No
|No
|No
|EXAMPLE

Common recurrent secondary finding for t(8;21) (add reference).
|}

<blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}

High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements almost invariably display a complex karyotype with many cytogenetic abnormalities<ref name=":0" /><ref name=":2" /><ref name=":4" />. Gains of chromosomes 8q and 12q are more common in HGBL-DH/TH than in cases with isolated MYC translocation<ref name=":8" />. 12q12-q15 copy-number gain is significantly more common in HGBL with MYC and BCL2 translocation than in cases with BCL6 translocation<ref name=":4" />.

Other common aberrations include<ref name=":4" />

{| class="wikitable sortable"
|-
!Chromosome Number!!Gain/Loss/Amp/LOH!!Region
|-
|3||Gain||p12.1-q29
|-
|7
|Gain
|p22.3-p11.1
|-
|12||Gain||p13.33-q21.31
|-
|1
|Loss
|p36.33-p36.32
|-
|6
|Loss
|q22.1-q23.2
|-
|15
|Loss
|q14-q21.3
|-
|1-3
|LOH
|1p32.3-3p21.31
|}
</blockquote>
==Characteristic Chromosomal Patterns==

Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')</span>

{| class="wikitable sortable"
|-
!Chromosomal Pattern
!Diagnostic Significance (Yes, No or Unknown)
!Prognostic Significance (Yes, No or Unknown)
!Therapeutic Significance (Yes, No or Unknown)
!Notes
|-
|EXAMPLE

Co-deletion of 1p and 18q
|Yes
|No
|No
|EXAMPLE:

See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
|}
==Gene Mutations (SNV / INDEL)==

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>

{| class="wikitable sortable"
|-
!Gene; Genetic Alteration!!'''Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)'''!!'''Prevalence (COSMIC /  TCGA / Other)'''!!'''Concomitant Mutations'''!!'''Mutually Exclusive Mutations'''
!'''Diagnostic Significance (Yes, No or Unknown)'''
!Prognostic Significance (Yes, No or Unknown)
!Therapeutic Significance (Yes, No or Unknown)
!Notes
|-
|EXAMPLE: TP53; Variable LOF mutations

EXAMPLE:

EGFR; Exon 20 mutations

EXAMPLE: BRAF; Activating mutations
|EXAMPLE: TSG
|EXAMPLE: 20% (COSMIC)

EXAMPLE: 30% (add Reference)
|EXAMPLE: IDH1 R123H
|EXAMPLE: EGFR amplification
|
|
|
|EXAMPLE:  Excludes hairy cell leukemia (HCL) (add reference).
<br />
|}
Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.


<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}

Due to the relatively recent classification of HGBL with MYC and BCL2 and/or BCL6 translocation as a specific pathological entity, combined with small sample sizes, comprehensive data on gene mutation prevalence is not currently available. However, several studies have shown the mutational profile of HGBL DH/TH to differ significantly from that of DLBCL, NOS. Frequently mutations are associated with apoptosis and cell cycle pathways known to be associated with poor prognosis in DLBCL patients, including SOCS1 non-truncating mutations and mutations in CREBBP and FOX01<ref name=":9" />. HGBL DH/TH also shows a significantly higher number of IGH and MYC mutations than DLBCL with isolated MYC translocation<ref name=":8" />. MYC hotspot mutations occur more frequently in cases in which the MYC translocation partner is an immunoglobulin gene, and are associated with high MYC protein expression<ref name=":12" />. Amongst the most frequently mutated genes, somatic CREBBP mutations have been shown to inhibit TP53 tumour suppressor activity through activation of the BCL6 oncoprotein<ref name=":9" />. KMT2D mutations consist primarily of frameshift deletions and stop gain alterations with subsequent loss of protein function<ref name=":9" />.

Amongst HGBL DH/TH cases, the nature of the secondary translocation also affects the mutational landscape, with TP53 mutations, associated with significantly worse overall survival, occurring more frequently in HGBL with MYC and BCL2 translocation than cases with MYC and BCL6 translocations or triple-hit tumours<ref name=":15">{{Cite journal|last=Gebauer|first=Niklas|last2=Bernard|first2=Veronica|last3=Gebauer|first3=Wolfgang|last4=Thorns|first4=Christoph|last5=Feller|first5=Alfred C.|last6=Merz|first6=Hartmut|date=2015-01-02|title=TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations|url=http://www.tandfonline.com/doi/full/10.3109/10428194.2014.907896|journal=Leukemia & Lymphoma|language=en|volume=56|issue=1|pages=179–185|doi=10.3109/10428194.2014.907896|issn=1042-8194}}</ref>.

In one study<ref name=":12" />, both HGBL with MYC and BCL2 translocations and triple-hit cases had a higher mutational load and more frequent mutations in BCL2, KMTD2, CREBBP, EZH2 and TNFRSF14 than DLBCL with isolated MYC translocation. These mutations are cardinal features of follicular lymphoma and are also commonly seen in DLBCL, NOS. In addition, BCL2 translocated cases harboured additional mutations (MYC, GNA13, TP53, P2RY8, PIM1, CCND3, B2M, EBF1 and S1PR2) associated with high-grade transformation of follicular lymphoma, suggesting a possible derivation from follicular lymphoma following acquisition of a MYC translocation.

Overall, HGBL with MYC and BCL6 translocation shows a different and more heterogenous mutation profile to those with MYC and BCL2 translocation. BCL10 and NOTCH2 mutations are most commonly enriched in MYC/BCL6 translocated cases<ref name=":12" />.

As HGBL is a genetically heterogenous disease, a multitude of gene mutations have been identified at varying levels of prevalence. The table below summarises the most common mutations identified from a number of studies<ref name=":12" /><ref name=":9" /><ref name=":15" /><ref name=":18" /><ref name=":21" /><ref name=":19" />, including only those with a prevalence greater than 20% in the data analysed.
{| class="wikitable sortable"
|-
!Gene!!Oncogene/Tumor Suppressor/Other!!Presumed Mechanism (LOF/GOF/Other; Driver/Passenger)!!Prevalence (COSMIC/TCGA/Other)
|-
|BCL2||Oncogene||GOF||57% (72/126)
|-
|KMT2D
|Tumour suppressor
|LOF
|54% (68/126)
|-
|CREBBP
|Tumour suppressor
|LOF
|47% (59/126)
|-
|MYC
|Oncogene
|GOF
|42% (53/126)
|-
|GNAI2
|Oncogene
|GOF
|40% (2/5)
|-
|IGLL5
|Not fully characterised
|
|40% (8/20)
|-
|EZH2
|Oncogene
|GOF
|39% (49/126)
|-
|TNFRSF14
|Tumour suppressor
|LOF
|33% (35/106)
|-
|SOCS1
|Tumour suppressor/oncogene
|LOF/GOF
|29% (33/112)
|-
|FOXO1
|Oncogene
|GOF
|29% (34/117)
|-
|IRF8
|Oncogene
|GOF
|29% (28/97)
|-
|TP53
|Tumour suppressor
|LOF
|25% (27/106)
|-
|DTX1
|Tumour suppressor
|LOF
|25% (23/92)
|-
|XPO1
|Oncogene
|GOF
|25% (2/8)
|-
|PIM1
|Oncogene
|GOF
|25% (25/101)
|-
|GNA13
|Tumour suppressor
|LOF
|25% (26/106)
|-
|HIST1H1E
|Oncogene
|GOF
|24% (24/101)
|-
|ID3
|Tumour suppressor
|LOF
|23% (7/31)
|-
|BCL7A
|Tumour suppressor
|LOF
|20% (1/5)
|-
|C10orf12
|Not fully characterised
|
|20% (1/5)
|-
|P2RY8
|Oncogene
|GOF
|20% (18/92)
|}
</blockquote>
==Epigenomic Alterations==

Although the role of epigenomics in HGBL specifically has been incompletely described, many of the genes most frequently mutated in HGBL have been shown to be epigenetic determinants in DLBCL. Such genes include EZH2, KMT2D and CREBBP, which encode proteins that are involved in two epigenetic switches at the promoter and enhancer regions of genes involved in the germinal centre reaction. These switches regulate the movement of germinal centre B-cells between the dark and light zones of the germinal centre and require the addition or removal of specific histone post-translational modifications to up- or down-regulate the target gene.<ref name=":23">{{Cite journal|last=Bakhshi|first=Tanner J.|last2=Georgel|first2=Philippe T.|date=2020-12|title=Genetic and epigenetic determinants of diffuse large B-cell lymphoma|url=http://dx.doi.org/10.1038/s41408-020-00389-w|journal=Blood Cancer Journal|volume=10|issue=12|doi=10.1038/s41408-020-00389-w|issn=2044-5385}}</ref>

BCL6 is an important regulatory gene, repressing, often in combination with EZH2, the expression of a multitude of genes involved in cell cycle regulation whilst affinity maturation is ongoing.  EZH2 encodes a histone methyltransferase which affects H3K27 methylation and its most common gain-of-function mutation has been shown in mouse models to cause a global increase of H3K27 trimethylation but with accompanying decreased expression of H3K27me3 at multiple loci<ref>{{Cite journal|last=Souroullas|first=George P.|last2=Jeck|first2=William R.|last3=Parker|first3=Joel S.|last4=Simon|first4=Jeremy M.|last5=Liu|first5=Jie-Yu|last6=Paulk|first6=Joshiawa|last7=Xiong|first7=Jessie|last8=Clark|first8=Kelly S.|last9=Fedoriw|first9=Yuri|date=2016-06|title=An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation|url=https://pubmed.ncbi.nlm.nih.gov/27135738|journal=Nature Medicine|volume=22|issue=6|pages=632–640|doi=10.1038/nm.4092|issn=1546-170X|pmc=4899144|pmid=27135738}}</ref>. When there is constitutive expression of BCL6 and a concurrent EZH2 mutation driving the repression of the promoter region of a common target gene, such as is sometimes observed in DLBCL, such repression may become permanent, leading to an oncogenic state.<ref name=":23" /> 

Similarly, inactivating CREBBP mutations within germinal centre B-cells prevent enhancer reactivation and, due to the role of CREBBP in acetylation of BCL6 and p53, impairs the cells’ ability to regulate these genes. Thus, inactivating CREBBP mutations can trap cells in the germinal centre reaction, being unable to differentiate whilst being exposed to mutagenic and therefore potentially oncogenic conditions.<ref name=":23" /> CREBBP and EP300, both histone acetyltransferases, are frequently mutated in DBLCL and mutations have been shown to promote oncogenesis by both inducing H3K27 deacetylation and activating the NOTCH signalling pathway, which is critical to the regulation of B-cell proliferation, migration and survival in lymphoma<ref>{{Cite journal|last=Huang|first=Yao-Hui|last2=Cai|first2=Kun|last3=Xu|first3=Peng-Peng|last4=Wang|first4=Li|last5=Huang|first5=Chuan-Xin|last6=Fang|first6=Ying|last7=Cheng|first7=Shu|last8=Sun|first8=Xiao-Jian|last9=Liu|first9=Feng|date=2021-01-11|title=CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis|url=http://dx.doi.org/10.1038/s41392-020-00437-8|journal=Signal Transduction and Targeted Therapy|volume=6|issue=1|doi=10.1038/s41392-020-00437-8|issn=2059-3635}}</ref>.

KMT2D mutants promote lymphomagenesis in part by impeding H3K4 methylation, driving enhanced proliferation in germinal centres and impeding terminal differentiation of B cells<ref name=":24" />. The extent to which KMT2D loss promotes lymphomagenesis appears to be affected by dysregulation of the expression of a number of other genes, including BCL2 and AICDA. KMT2D loss, in combination with increased BCL2 expression, has been shown in mouse models to increase lymphoma incidence from that of mice with wild type KMT2D, and the effect is greater for those with homozygous deletions<ref>{{Cite journal|last=Zhang|first=Jiyuan|last2=Dominguez-Sola|first2=David|last3=Hussein|first3=Shafinaz|last4=Lee|first4=Ji-Eun|last5=Holmes|first5=Antony B|last6=Bansal|first6=Mukesh|last7=Vlasevska|first7=Sofija|last8=Mo|first8=Tongwei|last9=Tang|first9=Hongyan|date=2015-09-14|title=Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis|url=http://dx.doi.org/10.1038/nm.3940|journal=Nature Medicine|volume=21|issue=10|pages=1190–1198|doi=10.1038/nm.3940|issn=1078-8956}}</ref><ref name=":24">{{Cite journal|last=Ortega-Molina|first=Ana|last2=Boss|first2=Isaac W.|last3=Canela|first3=Andres|last4=Pan|first4=Heng|last5=Jiang|first5=Yanwen|last6=Zhao|first6=Chunying|last7=Jiang|first7=Man|last8=Hu|first8=Deqing|last9=Agirre|first9=Xabier|date=2015-10|title=The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development|url=https://pubmed.ncbi.nlm.nih.gov/26366710|journal=Nature Medicine|volume=21|issue=10|pages=1199–1208|doi=10.1038/nm.3943|issn=1546-170X|pmc=4676270|pmid=26366710}}</ref>. Similarly the overexpression of AICDA, which encodes activation-induced cytidine deaminase (AID), an enzyme involved in somatic hypermutation, class switch recombination and gene conversion in the process of immunoglobulin diversification, has been shown in mice models to be associated with increased lymphoma incidence only in combination with KMT2D loss, and to be associated with more aggressive phenotypes than tumours with KMT2D deletion alone<ref name=":24" />.

==Genes and Main Pathways Involved==

Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table.'')</span>
{| class="wikitable sortable"
|-
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
|-
|EXAMPLE: BRAF and MAP2K1; Activating mutations
|EXAMPLE: MAPK signaling
|EXAMPLE: Increased cell growth and proliferation
|-
|EXAMPLE: CDKN2A; Inactivating mutations
|EXAMPLE: Cell cycle regulation
|EXAMPLE: Unregulated cell division
|-
|EXAMPLE:  KMT2C and ARID1A; Inactivating mutations
|EXAMPLE:  Histone modification, chromatin remodeling
|EXAMPLE:  Abnormal gene expression program
|}

<blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}
MYC is a proto-oncogene located at chromosome 8q24.2 which has been implicated in a variety of human cancers through its role as a regulator of multiple functions including cellular proliferation, DNA and protein synthesis and metabolism<ref>{{Cite journal|last=Cheah|first=Chan Yoon|last2=Oki|first2=Yasuhiro|last3=Westin|first3=Jason R.|last4=Turturro|first4=Francesco|date=2015-03|title=A clinician's guide to double hit lymphomas|url=https://onlinelibrary.wiley.com/doi/10.1111/bjh.13276|journal=British Journal of Haematology|language=en|volume=168|issue=6|pages=784–795|doi=10.1111/bjh.13276}}</ref>. In the process of B cell maturation, MYC is involved in multiple different intracellular pathways governing angiogenesis, differentiation and metabolism<ref name=":27">{{Cite journal|last=Korać|first=Petra|last2=Dotlić|first2=Snježana|last3=Matulić|first3=Maja|last4=Zajc Petranović|first4=Matea|last5=Dominis|first5=Mara|date=2017-04-04|title=Role of MYC in B Cell Lymphomagenesis|url=http://www.mdpi.com/2073-4425/8/4/115|journal=Genes|language=en|volume=8|issue=4|pages=115|doi=10.3390/genes8040115|issn=2073-4425|pmc=PMC5406862|pmid=28375188}}</ref>. MYC, not normally expressed by naïve B cells, is upregulated upon antigen stimulation and is crucial for germinal centre development, but is then subsequently suppressed by BCL6 and BLIMP1<ref>{{Cite journal|last=Karube|first=Kennosuke|last2=Campo|first2=Elias|date=2015-04|title=MYC alterations in diffuse large B-cell lymphomas|url=https://pubmed.ncbi.nlm.nih.gov/25805589|journal=Seminars in Hematology|volume=52|issue=2|pages=97–106|doi=10.1053/j.seminhematol.2015.01.009|issn=1532-8686|pmid=25805589}}</ref>. MYC translocation leads to increased MYC expression compared to non-translocated cases, regardless of translocation partner<ref>{{Cite journal|last=Bertrand|first=P.|last2=Bastard|first2=C.|last3=Maingonnat|first3=C.|last4=Jardin|first4=F.|last5=Maisonneuve|first5=C.|last6=Courel|first6=M.-N.|last7=Ruminy|first7=P.|last8=Picquenot|first8=J.-M.|last9=Tilly|first9=H.|date=2007-03|title=Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas|url=https://pubmed.ncbi.nlm.nih.gov/17230227|journal=Leukemia|volume=21|issue=3|pages=515–523|doi=10.1038/sj.leu.2404529|issn=0887-6924|pmid=17230227}}</ref>. Translocation of MYC to an immunoglobulin locus leads to overexpression of the MYC protein due to IG promoter driven constitutively active transcription<ref name=":28">{{Cite journal|last=Sesques|first=Pierre|last2=Johnson|first2=Nathalie A.|date=2017-01-19|title=Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements|url=https://ashpublications.org/blood/article/129/3/280/36006/Approach-to-the-diagnosis-and-treatment-of|journal=Blood|language=en|volume=129|issue=3|pages=280–288|doi=10.1182/blood-2016-02-636316|issn=0006-4971}}</ref>. MYC expression in lymphoma promotes cell proliferation and induces genomic instability<ref name=":28" /><ref>{{Cite journal|last=Meyer|first=Natalie|last2=Penn|first2=Linda Z.|date=2008-12|title=Reflecting on 25 years with MYC|url=http://dx.doi.org/10.1038/nrc2231|journal=Nature Reviews Cancer|volume=8|issue=12|pages=976–990|doi=10.1038/nrc2231|issn=1474-175X}}</ref>, however whilst MYC contributes to oncogenic changes, it can also paradoxically promote apoptosis and increase the expression of tumour suppressor TP53<ref name=":25" /><ref name=":27" />. MYC overexpression in isolation is insufficient to promote lymphomagenesis<ref name=":25">{{Cite journal|last=Riedell|first=Peter A.|last2=Smith|first2=Sonali M.|date=2018-12-15|title=Double hit and double expressors in lymphoma: Definition and treatment|url=https://onlinelibrary.wiley.com/doi/10.1002/cncr.31646|journal=Cancer|language=en|volume=124|issue=24|pages=4622–4632|doi=10.1002/cncr.31646|issn=0008-543X}}</ref><ref name=":27" />, and MYC translocation is postulated to occur as a secondary genetic abnormality contributing to oncogenesis and an aggressive phenotype<ref name=":0" /><ref name=":27" />.  

BCL2, an oncogene at chromosome 18q21.3, acts to inhibit apoptosis to maintain cellular viability, but is, in normal cells, itself downregulated by the BH3 family of proteins<ref name=":14" />. BCL2 overexpression resulting from chromosomal translocation confers apoptosis resistance to B-cells and allows them to proliferate within the germinal centre in which the BCL2 protein is not normally expressed<ref>{{Cite journal|last=Tomita|first=Naoto|date=2011|title=BCL2 and MYC Dual-Hit Lymphoma/Leukemia|url=http://dx.doi.org/10.3960/jslrt.51.7|journal=Journal of Clinical and Experimental Hematopathology|volume=51|issue=1|pages=7–12|doi=10.3960/jslrt.51.7|issn=1880-9952}}</ref>. BCL2 dysregulation acts synergistically with increased MYC translation to drive oncogenesis<ref name=":14" />.

BCL6, located on chromosome 3q27.3 encodes a protein which suppresses the activity of P53, MYC and BCL2 and thus acts as a transcriptional repressor, contributing to the regulation of activation, differentiation and apoptosis in the germinal centre reaction<ref name=":25" /><ref>{{Cite journal|last=Basso|first=Katia|last2=Dalla-Favera|first2=Riccardo|date=2010|title=BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis|url=https://pubmed.ncbi.nlm.nih.gov/20510734|journal=Advances in Immunology|volume=105|pages=193–210|doi=10.1016/S0065-2776(10)05007-8|issn=1557-8445|pmid=20510734}}</ref><ref name=":26">{{Cite journal|last=Basso|first=Katia|last2=Dalla-Favera|first2=Riccardo|date=2012-04-13|title=Roles of BCL6 in normal and transformed germinal center B cells|url=http://dx.doi.org/10.1111/j.1600-065x.2012.01112.x|journal=Immunological Reviews|volume=247|issue=1|pages=172–183|doi=10.1111/j.1600-065x.2012.01112.x|issn=0105-2896}}</ref>. In normal B-cell development, expression of the BCL6 protein is restricted to the germinal centre stage of differentiation<ref name=":26" />. Chromosomal translocations of BCL6 involve promoter substitution, where heterologous promoters from other chromosomes are relocated to the 5' end of the BCL6 gene<ref name=":26" />. Commonly, these promoters show persistent activity in post germinal centre B-cells, causing abnormal BCL6 expression by prevention of its physiological downregulation<ref name=":26" />. It is postulated that deregulated BCL6 expression contributes to lymphomagenesis by promoting a tolerance to DNA damage and hence oncogenic mutations<ref name=":26" />.
</blockquote>
==Genetic Diagnostic Testing Methods==

Histologically, HGBL with MYC and BCL2 and/or BCL6 rearrangements is often indistinguishable from other high-grade lymphomas and the only method to ensure detection of all cases is universal investigation of DLBCL, NOS by MYC FISH with further testing for BCL2 and BCL6 translocations where MYC rearrangement is detected<ref name=":0" /><ref name=":6" /><ref name=":14" /><ref name=":16">{{Cite journal|last=Chaganti|first=Sridhar|last2=Illidge|first2=Tim|last3=Barrington|first3=Sally|last4=Mckay|first4=Pam|last5=Linton|first5=Kim|last6=Cwynarski|first6=Kate|last7=McMillan|first7=Andrew|last8=Davies|first8=Andy|last9=Stern|first9=Simon|date=2016|title=Guidelines for the management of diffuse large B-cell lymphoma|url=https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.14136|journal=British Journal of Haematology|language=en|volume=174|issue=1|pages=43–56|doi=10.1111/bjh.14136|issn=1365-2141}}</ref>. In environments with restricted resources, limiting screening to GCB subtype tumours would limit FISH testing to 50-62% of the DLBCL population, whilst still detecting >99% of tumours with MYC and BCL2 translocation<ref name=":6" />.

Use of a MYC break-apart probe or IG/MYC dual fusion probe as the sole method of detection of MYC rearrangement has the potential to yield false-negative results in cases of 8q24 breakpoints occurring very close to the MYC gene region and non-IG MYC-rearrangement partners, respectively, and concurrent use of both break apart and IGH/MYC dual fusion probes is therefore recommended if possible<ref name=":6" /><ref name=":13" /><ref name=":17">{{Cite journal|last=Hilton|first=Laura K.|last2=Tang|first2=Jeffrey|last3=Ben-Neriah|first3=Susana|last4=Alcaide|first4=Miguel|last5=Jiang|first5=Aixiang|last6=Grande|first6=Bruno M.|last7=Rushton|first7=Christopher K.|last8=Boyle|first8=Merrill|last9=Meissner|first9=Barbara|date=2019-10-31|title=The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH|url=https://ashpublications.org/blood/article/134/18/1528/374992/The-doublehit-signature-identifies-doublehit|journal=Blood|language=en|volume=134|issue=18|pages=1528–1532|doi=10.1182/blood.2019002600|issn=0006-4971|pmc=PMC6839951|pmid=31527075}}</ref><ref>{{Cite journal|last=Muñoz-Mármol|first=Ana M|last2=Sanz|first2=Carolina|last3=Tapia|first3=Gustavo|last4=Marginet|first4=Ruth|last5=Ariza|first5=Aurelio|last6=Mate|first6=José L|date=2013-09|title=MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection|url=https://onlinelibrary.wiley.com/doi/10.1111/his.12178|journal=Histopathology|language=en|volume=63|issue=3|pages=418–424|doi=10.1111/his.12178}}</ref><ref>{{Cite journal|last=May|first=Philippa C.|last2=Foot|first2=Nicola|last3=Dunn|first3=Robert|last4=Geoghegan|first4=Helen|last5=Neat|first5=Michael J.|date=2010-04|title=Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: implications for cytogenetic testing|url=https://linkinghub.elsevier.com/retrieve/pii/S0165460809007006|journal=Cancer Genetics and Cytogenetics|language=en|volume=198|issue=1|pages=71–75|doi=10.1016/j.cancergencyto.2009.12.010}}</ref>. Use of IGL/MYC and/or IGK/MYC dual fusion probes can follow, if required, to confirm the presence or absence of an IG fusion partner, which has implications for prognostication.

There are, however, limitations to FISH testing. A subset of HGBCL DH/TH harbour MYC and/or BCL2 rearrangements that are cryptic to FISH, for example via cryptic enhancer insertions near MYC of insufficient size to separate the break apart probes sufficiently for detection by FISH<ref name=":17" />. Such cases, identified via whole genome sequencing, were in one study found to account for 19% of all HGBL DH/TH tumours, with the authors recommending the use of gene expression profiling rather than FISH to identify HGBL DH/TH cases<ref name=":17" />. Furthermore, false-positive or false-negative FISH results can occur due to probe type or different numbers of malignant lymphoid cells in different specimens (eg BM aspirate vs FFPE tissue) as well as inter-observer variability<ref name=":2" />.

Several authors<ref name=":18">{{Cite journal|last=Song|first=Joo Y.|last2=Perry|first2=Anamarija M.|last3=Herrera|first3=Alex F.|last4=Chen|first4=Lu|last5=Skrabek|first5=Pamela|last6=Nasr|first6=Michel R.|last7=Ottesen|first7=Rebecca A.|last8=Nikowitz|first8=Janet|last9=Bedell|first9=Victoria|date=2021-03-15|title=Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP|url=http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-20-2378|journal=Clinical Cancer Research|language=en|volume=27|issue=6|pages=1671–1680|doi=10.1158/1078-0432.CCR-20-2378|issn=1078-0432}}</ref><ref name=":21">{{Cite journal|last=Wright|first=George W.|last2=Huang|first2=Da Wei|last3=Phelan|first3=James D.|last4=Coulibaly|first4=Zana A.|last5=Roulland|first5=Sandrine|last6=Young|first6=Ryan M.|last7=Wang|first7=James Q.|last8=Schmitz|first8=Roland|last9=Morin|first9=Ryan D.|date=2020-04|title=A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications|url=https://linkinghub.elsevier.com/retrieve/pii/S1535610820301550|journal=Cancer Cell|language=en|volume=37|issue=4|pages=551–568.e14|doi=10.1016/j.ccell.2020.03.015}}</ref><ref>{{Cite journal|last=Ennishi|first=Daisuke|last2=Jiang|first2=Aixiang|last3=Boyle|first3=Merrill|last4=Collinge|first4=Brett|last5=Grande|first5=Bruno M.|last6=Ben-Neriah|first6=Susana|last7=Rushton|first7=Christopher|last8=Tang|first8=Jeffrey|last9=Thomas|first9=Nicole|date=2019-01-20|title=Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma|url=https://ascopubs.org/doi/10.1200/JCO.18.01583|journal=Journal of Clinical Oncology|language=en|volume=37|issue=3|pages=190–201|doi=10.1200/JCO.18.01583|issn=0732-183X|pmc=PMC6804880|pmid=30523716}}</ref><ref name=":19">{{Cite journal|last=Sha|first=Chulin|last2=Barrans|first2=Sharon|last3=Cucco|first3=Francesco|last4=Bentley|first4=Michael A.|last5=Care|first5=Matthew A.|last6=Cummin|first6=Thomas|last7=Kennedy|first7=Hannah|last8=Thompson|first8=Joe S.|last9=Uddin|first9=Rahman|date=2019-01-20|title=Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy|url=https://ascopubs.org/doi/10.1200/JCO.18.01314|journal=Journal of Clinical Oncology|language=en|volume=37|issue=3|pages=202–212|doi=10.1200/JCO.18.01314|issn=0732-183X|pmc=PMC6338391|pmid=30523719}}</ref> have proposed refined molecular subtypes of DLBCL based on gene expression profiling and/or mutation status, within which subtypes not all tumours are double- or triple- hit on the basis of FISH. In addition to overcoming translocations cryptic to FISH, several of these gene signatures have been shown to provide additional information on prognosis with one study showing that double hit lymphomas lacking the molecular high grade signature showed outcomes no worse than other germinal centre B-cell like cases<ref name=":19" />.

==Familial Forms==

There is currently no known familial association.

==Additional Information==

Put your text here

==Links==

[[HAEM4:High-Grade B-cell Lymphoma]]

Put your links here (use "Link" icon at top of page)

==References==
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted.''</span> <span style="color:#0070C0">''If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">) </span> <references />

'''

==Notes==
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.

<nowiki>*</nowiki>''Citation of this Page'': “Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Diffuse_large_B-cell_lymphoma_/_high_grade_B-cell_lymphoma_with_MYC_and_BCL2_rearrangements</nowiki>.
==Other Sections==
Cancer Sub-Classification/Subtype


High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements


Definition/Description of Disease


High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is a clinically aggressive lymphoma with poor prognosis. It is defined as a distinct entity which includes mature B cell neoplasms harbouring both MYC and BCL2 and/or BCL6 rearrangements, as detected by a cytogenetic/molecular method such as FISH, except for cases of proven follicular lymphoma in the absence of a concurrent high-grade component, or where the disease is classified as B-lymphoblastic leukaemia/lymphoma<ref name=":0">Kluin PM, et al,, (2017). High-grade B-cell lymphoma, in World Health Organisation Classificaiton of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4<sup>th</sup> edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p330-334.</ref>.


Synonyms/Terminology


“Double-Hit Lymphoma (HGBL-DH)” in cases with MYC and BCL2 OR BCL6 rearrangement.

“Triple-Hit Lymphoma (HGBL-TH)” in cases with MYC, BCL2 AND BCL6 rearrangement.

Obsolete: B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma


Epidemiology/Prevalence


*HGBL DH/TH accounts for 3-9% of diffuse large B-cell lymphoma and approximately 13.3% of the germinal centre B-cell-like subtype<ref name=":0" /><ref name=":6">{{Cite journal|last=Scott|first=David W.|last2=King|first2=Rebecca L.|last3=Staiger|first3=Annette M.|last4=Ben-Neriah|first4=Susana|last5=Jiang|first5=Aixiang|last6=Horn|first6=Heike|last7=Mottok|first7=Anja|last8=Farinha|first8=Pedro|last9=Slack|first9=Graham W.|date=2018-05-03|title=High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology|url=https://pubmed.ncbi.nlm.nih.gov/29475959|journal=Blood|volume=131|issue=18|pages=2060–2064|doi=10.1182/blood-2017-12-820605|issn=1528-0020|pmc=6158813|pmid=29475959}}</ref><ref name=":1">{{Cite journal|last=Akyurek|first=Nalan|last2=Uner|first2=Aysegul|last3=Benekli|first3=Mustafa|last4=Barista|first4=Ibrahim|date=2012-09-01|title=Prognostic significance of MYC , BCL2 , and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab: MYC , BCL2 , BCL6 Rearrangements in DLBCL|url=https://onlinelibrary.wiley.com/doi/10.1002/cncr.27396|journal=Cancer|language=en|volume=118|issue=17|pages=4173–4183|doi=10.1002/cncr.27396}}</ref><ref name=":7">{{Cite journal|last=Copie-Bergman|first=Christiane|last2=Cuillière-Dartigues|first2=Peggy|last3=Baia|first3=Maryse|last4=Briere|first4=Josette|last5=Delarue|first5=Richard|last6=Canioni|first6=Danielle|last7=Salles|first7=Gilles|last8=Parrens|first8=Marie|last9=Belhadj|first9=Karim|date=2015-11-26|title=MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study|url=https://ashpublications.org/blood/article/126/22/2466/34616/MYCIG-rearrangements-are-negative-predictors-of|journal=Blood|language=en|volume=126|issue=22|pages=2466–2474|doi=10.1182/blood-2015-05-647602|issn=0006-4971}}</ref><ref name=":2">{{Cite journal|last=Kim|first=Heyjin|last2=Kim|first2=Hee-Jin|last3=Kim|first3=Sun-Hee|date=2020-09-01|title=Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens|url=http://annlabmed.org/journal/view.html?doi=10.3343/alm.2020.40.5.361|journal=Annals of Laboratory Medicine|language=en|volume=40|issue=5|pages=361–369|doi=10.3343/alm.2020.40.5.361|issn=2234-3806|pmc=PMC7169621|pmid=32311849}}</ref><ref name=":12">{{Cite journal|last=Cucco|first=Francesco|last2=Barrans|first2=Sharon|last3=Sha|first3=Chulin|last4=Clipson|first4=Alexandra|last5=Crouch|first5=Simon|last6=Dobson|first6=Rachel|last7=Chen|first7=Zi|last8=Thompson|first8=Joe Sneath|last9=Care|first9=Matthew A.|date=2020-05|title=Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit|url=http://www.nature.com/articles/s41375-019-0691-6|journal=Leukemia|language=en|volume=34|issue=5|pages=1329–1341|doi=10.1038/s41375-019-0691-6|issn=0887-6924|pmc=PMC7192846|pmid=31844144}}</ref>
*HGBL DH/TH accounts for approximately 1.7% of activated B-cell-like diffuse large B-cell lymphoma<ref name=":6" />
**These tumours overwhelmingly show concurrent MYC and BCL6 translocations, and the existence of activated B-cell-like high grade B cell lymphoma with BCL2 translocation is controversial<ref name=":6" />
*MYC translocations occur concurrently with BCL2 translocations in 57-87% of cases and with BCL6 translocations in 5-30% of cases. MYC, BCL2 and BCL6 translocations ("triple hit") are present in 7-15%<ref name=":8">{{Cite journal|last=Aukema|first=S. M.|last2=Kreuz|first2=M.|last3=Kohler|first3=C. W.|last4=Rosolowski|first4=M.|last5=Hasenclever|first5=D.|last6=Hummel|first6=M.|last7=Kuppers|first7=R.|last8=Lenze|first8=D.|last9=Ott|first9=G.|date=2014-04-01|title=Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma|url=http://www.haematologica.org/cgi/doi/10.3324/haematol.2013.091827|journal=Haematologica|language=en|volume=99|issue=4|pages=726–735|doi=10.3324/haematol.2013.091827|issn=0390-6078|pmc=PMC3971083|pmid=24179151}}</ref><ref name=":3">{{Cite journal|last=Petrich|first=Adam M.|last2=Gandhi|first2=Mitul|last3=Jovanovic|first3=Borko|last4=Castillo|first4=Jorge J.|last5=Rajguru|first5=Saurabh|last6=Yang|first6=David T.|last7=Shah|first7=Khushboo A.|last8=Whyman|first8=Jeremy D.|last9=Lansigan|first9=Frederick|date=2014-10-09|title=Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis|url=https://ashpublications.org/blood/article/124/15/2354/33469/Impact-of-induction-regimen-and-stem-cell|journal=Blood|language=en|volume=124|issue=15|pages=2354–2361|doi=10.1182/blood-2014-05-578963|issn=0006-4971}}</ref><ref name=":9">{{Cite journal|last=Evrard|first=Solène M.|last2=Péricart|first2=Sarah|last3=Grand|first3=David|last4=Amara|first4=Nadia|last5=Escudié|first5=Frédéric|last6=Gilhodes|first6=Julia|last7=Bories|first7=Pierre|last8=Traverse-Glehen|first8=Alexandra|last9=Dubois|first9=Romain|date=2019-04|title=Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements|url=http://www.haematologica.org/lookup/doi/10.3324/haematol.2018.198572|journal=Haematologica|language=en|volume=104|issue=4|pages=e154–e157|doi=10.3324/haematol.2018.198572|issn=0390-6078|pmc=PMC6442958|pmid=30309852}}</ref>
*The diagnosis is slightly more common in males
*Median age at diagnosis is 6<sup>th</sup> to 7<sup>th</sup> decade<ref name=":0" /><ref name=":4">{{Cite journal|last=Miyaoka|first=Masashi|last2=Kikuti|first2=Yara Y.|last3=Carreras|first3=Joaquim|last4=Ikoma|first4=Haruka|last5=Hiraiwa|first5=Shinichiro|last6=Ichiki|first6=Akifumi|last7=Kojima|first7=Minoru|last8=Ando|first8=Kiyoshi|last9=Yokose|first9=Tomoyuki|date=2018-02|title=Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements|url=https://www.nature.com/articles/modpathol2017134|journal=Modern Pathology|language=en|volume=31|issue=2|pages=313–326|doi=10.1038/modpathol.2017.134|issn=1530-0285}}</ref>

[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases D]]